Previous 10 | Next 10 |
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human t...
2023-11-07 12:51:35 ET Gainers: PaxMedica ( PXMD ) +78% . Jaguar Global Growth Corp I ( JGGC ) +62% . Transmedics Group ( TMDX ) +54% . Baiyu Holdings ( BYU ) +48% . Fathom Digital Manufacturing Corporation ( FATH ) +46% . Ko...
2023-11-06 12:51:18 ET Gainers: MSP Recovery ( LIFW ) +458% . Bluegreen Vacations Holding Corporation ( BVH ) +106% . Tenon Medical ( TNON ) +72% . Cano Health ( CANO ) +43% . Cheetah Net Supply Chain Service ( CTNT ) +36% . ...
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, to...
2023-09-07 10:00:14 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-08-23 11:57:49 ET Organovo Holdings ( NASDAQ: ONVO ) is up 4% in Wednesday morning trading after the company said that the first clinical trials for ulcerative colitis FXR314 would begin two years ahead of schedule. The original plan was that they would begin in 2025....
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of hu...
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human diseas...
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanc...
Summary ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. While the larger names in the portfolio do appear to belong, the bulk of the fund is in up-and-coming names, pre-profit, that feel like acquisition i...
News, Short Squeeze, Breakout and More Instantly...
Organovo Holdings Inc. Company Name:
ONVO Stock Symbol:
NASDAQ Market:
Chinese EV maker Nio Inc‘s (NYSE:NIO) new sub-brand Onvo will be headed by former Vice President of Marketing at Disney, Ai Tiecheng. Interes...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company...
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-q...